Novartis AG ADR (NVS): Price and Financial Metrics

Novartis AG ADR (NVS): $93.52

0.82 (-0.87%)

POWR Rating

Component Grades

Momentum

C

Stability

B

Sentiment

Quality

B

Add NVS to Watchlist
Sign Up

NVS Price/Volume Stats

Current price $93.52 52-week high $108.78
Prev. close $94.34 52-week low $92.19
Day low $93.41 Volume 2,099,600
Day high $95.05 Avg. volume 1,491,308
50-day MA $99.24 Dividend yield 2.63%
200-day MA $99.90 Market Cap 198.22B

NVS Stock Price Chart Interactive Chart >


Novartis AG ADR (NVS) Company Bio


Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, MassachusettsUnited States (global research). It is one of the largest pharmaceutical companies in the world. (Source:Wikipedia)


NVS Latest News Stream


Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream


Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Why Is Cytokinetics (CYTK) Stock Up 70% Today?

With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.

Josh Enomoto on InvestorPlace | December 27, 2023

Novartis (NVS) Outperforms Broader Market: What You Need to Know

Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.

Yahoo | December 27, 2023

The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours

Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.

Yahoo | December 26, 2023

Novartis (NVS) Stock Moves -1.17%: What You Should Know

Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.

Yahoo | December 20, 2023

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Yahoo | December 20, 2023

Read More 'NVS' Stories Here

NVS Price Returns

1-mo -3.86%
3-mo -11.03%
6-mo -0.30%
1-year 3.45%
3-year 21.40%
5-year 44.95%
YTD -5.11%
2023 20.92%
2022 6.47%
2021 -5.12%
2020 2.08%
2019 28.03%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!